London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of DataRevive.
Validant, a leading transatlantic quality, compliance and regulatory consulting group, has acquired DataRevive, a regulatory strategy and consultancy firm that focuses on supporting pharma and biotech to navigate the regulatory approval pathway for global clients in the US market.
Validant’s acquisition of DataRevive is part of its international growth strategy through both organic expansion and selective acquisitions and follows its partnership with GHO Capital, a leading specialist healthcare investment adviser based in London, in December 2018.
The combination of DataRevive and Validant will strengthen and expand the combined group’s service offering across regulatory driven life science consulting and allow both businesses to better serve their clients across the development lifecycle.
Established in 2016 by Audrey Jia, CEO, DataRevive is constructed around a high-quality partner base, with a mixture of ex-FDA and industry employees that bring unique expertise into the business. DataRevive focuses on novel therapeutics and biologics, the fastest growth segments of the market.
The acquisition adds a new location in Washington D.C. to complement Validant’s existing footprint in San Francisco, the Research Triangle Park in North Carolina and Cork, Ireland. With many international clients, DataRevive also broadens the group’s exposure to and expertise in significant new growth markets.
Commenting on the announcement, Brian Burns, CEO of Validant said: “We’re delighted to announce our acquisition of DataRevive and are excited about the combination with Validant. The DataRevive team brings a wealth of knowledge and new expertise into the business, complementing the Validant team. Together, we are in a better position to support our existing and new clients manage their regulatory and quality needs.”
“Joining forces with Validant will provide new commercial channels to deliver our services to a broader array of global biopharma customers. It will also strengthen our capability to provide world class quality and compliance services to enable our clients to achieve and maintain marketing applications globally” said Audrey Jia, CEO of DataRevive. “Our team are looking forward to being able to leverage the Validant network and best-in-class operating model to support a broader and growing customer base.”